Few studies have evaluated the waning of vaccine effectiveness against severe outcomes caused by SARS-CoV-2 Omicron infection. Hong Kong is providing inactivated and mRNA vaccines, but the population had limited protection from natural infections before the Omicron variant emerged.
Researchers at Moffitt Cancer Center are investigating new treatment approaches for this patient population. In a new article published in the International Journal of Radiation Oncology, Biology and Physics, our team of physicians, led by Daniel Oliver, M.D., and Stephen Rosenberg, M.D., shows that stereotactic body radiotherapy, or SBRT, is an effective treatment for patients with early stage lung neuroendocrine tumors.
Papers on the use of AI in physiologically based pharmacokinetic modeling, how mild allergic airway responses may increase cardiovascular risk, and how single-cell transcriptomes can show dose-dependent disruption of hepatic zonation by TCDD are featured in lastest issue of Toxicological Sciences.
Pharmaceutical synthesis is often quite complex; simplifications are needed to speed up the initial phase of drug development and lower the cost of generic production.
New research has found some antidepressants may be effective in treating certain chronic pain conditions, but others lack convincing evidence on their effectiveness.
A UCLA-led study provides the first scientific evidence that brick and mortar pharmacies in Northern Mexican tourist towns are selling counterfeit pills containing fentanyl, heroin, and methamphetamine. These pills are sold mainly to US tourists, and are often passed off as controlled substances such as Oxycodone, Percocet, and Adderall.
The FDA cleared SCINTIX biology-guided radiotherapy to treat patients with lung and bone tumors. These tumors may arise from primary cancers or from metastatic lesions spread from other cancers in the body. The breakthrough nature of SCINTIX technology lies in its ability to detect and then treat multiple moving tumors.
Despite concerns over antimicrobial resistance, global antimicrobial use in animals could increase by 8% by 2030.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Kevin Garey, professor of pharmacy practice and translational research at the University of Houston College of Pharmacy is reporting the first well-controlled study to demonstrate that a microbiome therapeutic, SER-109, is associated with significant quality of life improvement in patients with the debilitating recurrent infection and disease caused by Clostridium difficile (or C. diff).
Below are some of the latest articles that have been added to the Surgery and the Transplantation channels on Newswise, a free source for journalists.
Reductions in violence are seen in individuals using Beta adrenergic-blocking agents (β-blockers) compared with periods that they are not taking the medication, in a study published January 31st in the open access journal PLOS Medicine. If the findings are confirmed by other studies, β-blockers could be considered as a way to manage aggression and hostility in individuals with psychiatric conditions.
A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as the most important issues for them in considering whether to take PrEP.
UC San Diego scientists developed an artificial intelligence tool that could accelerate the development of new high affinity antibody drugs.
Inmazeb (REGN-EB3), developed by Regeneron, is a three-antibody cocktail designed to target the Ebola virus glycoprotein. The drug was first approved for clinical use in October 2020, but its exact mechanism of action has remained unclear.
Malgré les recommandations, le traitement de première intention de l'état de mal épileptique est souvent inapproprié. Des études suggèrent que jusqu'à deux tiers des patients reçoivent des doses subcliniques de benzodiazépines, soit avant d'arriver à l'hôpital, soit pendant un traitement hospitalier d'urgence. Existe-t-il des solutions ?
A team of researchers from the Cancer Science Institute of Singapore at the National University of Singapore has breathed new life into an existing drug — combatting a type of blood cancer called T-cell acute lymphoblastic leukaemia, or T-ALL. The drug, called PIK-75, was initially discovered over a decade ago but was dismissed in favour of newer ones. Now, it has made a comeback that deems it unmissable — the researchers established that the drug could block not just one but two crucial cancer-causing pathways of T-ALL, enabling them to develop new treatments that could effectively stem the disease.
Inaccurately recording the start of anesthesia care during a procedure is common and results in significant lost billing time for anesthesia practices and medical centers, suggests a study being presented at the American Society of Anesthesiologists’ ADVANCE 2023, the Anesthesiology Business Event.
Expanding anesthesiology residency programs — even in the absence of federal funding — may help medical institutions save staffing costs and address projected shortages of anesthesia care professionals, suggests a first-of-its-kind study being presented at the American Society of Anesthesiologists’ ADVANCE 2023, the Anesthesiology Business Event.
The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.
GRF's leadership awards will be presented at the Glaucoma 360 Annual Gala on February 2, 2023 at the iconic Westin St. Francis Hotel in San Francisco.
Santen will receive GRF’s highest honor, the Catalyst Award, at the Glaucoma 360 Annual Gala on February 2, 2023, in San Francisco.
Long-term treatment of healthy middle-aged mice with a cancer drug increases lifespan by 10% on average, equivalent to 3 years.
R. Scott Struthers, Ph.D., has been awarded the Endocrine Society’s John D. Baxter Prize for Entrepreneurship for his contributions to drug discovery and development programs for endocrine diseases, the Society announced today.
Female lymphoma patients undergoing the morning chemotherapy treatment show a lower survival probability than those undergoing the afternoon treatment.
Just as a choreographer’s notation tells a dancer to strike a particular pose, an enzyme newly discovered by Rice University scientists is able to tell specific molecules precisely how to arrange themselves, down to the angle of single hydrogen bonds.
Nucleic acid-targeting photodynamic therapy (PDT) is a promising type of targeted therapy that is being actively researched. This treatment relies on special photosensitizers, a type of drug that binds at specific locations in a cell’s DNA.
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
X-linked adrenoleukodystrophy (X-ALD) is the most common of a group of around 50 rare diseases of the white matter of the brain, the so-called leukodystrophies.
States that permit recreational use of cannabis see a reduction in demand for prescription codeine, an opioid with a high potential for misuse.
James Collins III, Ph.D., Associate Professor of Pharmacology at UT Southwestern Medical Center, will receive the 2023 Edith and Peter O’Donnell Award in Biological Sciences from The Academy of Medicine, Engineering and Science of Texas (TAMEST) for broadening understanding of schistosomiasis.
New UCLA-led research suggests that antiretroviral drugs called TAF and TDF directly reduce energy production by mitochondria, structures inside cells that generate the power that cells use to function. Both drugs led to reduced cellular oxygen consumption rates, a measure of the ability of the mitochondria to produce energy, compared with controls.
This basic scientific research provides a comprehensive structural framework that should help drug developers rationally design safer drugs to relieve severe pain.
Patients hospitalized with fractures typically receive an injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots.
Indiana University researchers have potentially discovered a new way to block the brain’s reward response to opioids, reducing their potential for addiction without reducing their therapeutic aspects.
If pharmaceutical companies shared their intellectual property rights to vaccines with the global community, millions of lives could be saved in future pandemics, according to a new paper co-authored by faculty at Binghamton University, State University of New York.
Research on fungi underway at the University of Kansas has helped transform tough-to-recycle plastic waste from the Pacific Ocean into key components for making pharmaceuticals.
A novel peptide designed by University of California, Irvine researchers has been found to suppress the damaging lung inflammation seen in acute respiratory distress syndrome, or ARDS. Their study, which appears in iScience, describes the first specific treatment designed to prevent the deadly disease, which can appear in patients with severe lung injury from infections with bacteria and viruses, like pneumonia, flu, respiratory syncytial virus (RSV) and COVID-19.
A first-of-its-kind study identifies mechanisms that explain how a drug commonly used to treat HIV and hepatitis causes kidney disease and kidney injury. The study is published ahead of print in Function.
It’s ‘lights out’ for antibiotic-resistant superbugs as next-generation light-activated nanotech proves it can eradicate some of the most notorious and potentially deadly bacteria in the world.
Although rare compared to adult liver cancers, hepatoblastoma is the most common pediatric liver malignancy, and its incidence is increasing.
The Society of Laboratory Automation and Screening (SLAS), announces the appointment of Lesley Mathews, Ph.D., as its new Scientific Director, effective January 16.
Brain structures which could predict an individual’s predisposition to accidental awareness under anaesthetic have been identified for the first time by neuroscientists in Trinity College Dublin.
Researchers at the University of Colorado Anschutz Medical Campus have discovered a drug combination that may offer a better prognosis for children diagnosed with MYC amplified Medulloblastoma, an often deadly form of brain cancer.
RUDN University chemists, biologists and physicians have found a simple way to predict the properties of compounds of drugs with metals. This can be done using topological indices - numbers that describe the structure of the molecule. The results will help finding new metal complexes that will improve the activity of existing drugs.
The U.S. Food and Drug Administration (FDA) recently granted approval to Lecanemab, the first Alzheimer’s disease treatment to win approval since the largely failed rollout of Aduhelm two years ago.
Benjamin K. Mizell, MD, an anesthesiologist with a proven track record of leading major Mass Eye and Ear initiatives including its electronic medical record integration, has been named chief of Anesthesia at Mass Eye and Ear.
Promising results from an ongoing clinical trial a three-drug treatment may improve survival in patients with newly diagnosed multiple myeloma who have undergone preliminary treatment followed by a stem cell transplant.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
